Arbutus Biopharma Corp [ABUS] stock is trading at $3.22, up 1.58%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ABUS shares have gain 3.21% over the last week, with a monthly amount drifted -0.62%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arbutus Biopharma Corp [NASDAQ: ABUS] stock has seen the most recent analyst activity on February 02, 2022, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, Jefferies started tracking the stock with Hold rating on February 25, 2021, and set its price target to $5. On December 17, 2020, H.C. Wainwright initiated with a Buy rating and assigned a price target of $10 on the stock. Robert W. Baird downgraded its rating to a Neutral. Wedbush upgraded its rating to Outperform for this stock on May 19, 2020. In a note dated March 06, 2020, Chardan Capital Markets upgraded an Buy rating on this stock but restated the target price of $5.
Arbutus Biopharma Corp [ABUS] stock has fluctuated between $2.70 and $4.72 over the past year. Currently, Wall Street analysts expect the stock to reach $8.5 within the next 12 months. Arbutus Biopharma Corp [NASDAQ: ABUS] shares were valued at $3.22 at the most recent close of the market. An investor can expect a potential return of 163.98% based on the average ABUS price forecast.
Analyzing the ABUS fundamentals
Arbutus Biopharma Corp [NASDAQ:ABUS] reported sales of 6.40M for the trailing twelve months, which represents a growth of 15.14%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at -12.88%, Pretax Profit Margin comes in at -11.96%, and Net Profit Margin reading is -11.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -0.75 and Total Capital is -0.84. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.14 points at the first support level, and at 3.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.27, and for the 2nd resistance point, it is at 3.31.
Ratios To Look Out For
For context, Arbutus Biopharma Corp’s Current Ratio is 6.01. Further, the Quick Ratio stands at 6.01, while the Cash Ratio is 1.91. Considering the valuation of this stock, the price to sales ratio is 96.36, the price to book ratio is 7.79.
Transactions by insiders
Recent insider trading involved McElhaugh Michael J., Director, that happened on Apr 21 ’25 when 0.25 million shares were purchased. Director, McElhaugh Michael J. completed a deal on Apr 15 ’25 to buy 53114.0 shares. Meanwhile, Officer Sofia Michael J. bought 0.25 million shares on Mar 31 ’25.
